From:  Osimertinib nano-niosomes: surfactant effects, release kinetics, and cytotoxicity studies

 Composition of osimertinib niosomal formulations.

FormulationDrug (mg)Final concentration (mg/mL)Cholesterol: surfactant ratioSurfactant type
F110 mg1 mg/mL1:1Span 60
F210 mg1 mg/mL1:1Tween 60
F310 mg1 mg/mL1:1Pluronic F-127
F410 mg1 mg/mL1:1Brij 52 (C16E2)